CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy
Recruiting · NCT06135909 · Observational (researchers observe without assigning treatment) · Lead sponsor: Chinese Pulmonary Vascular Disease Research Group
View the official record on ClinicalTrials.gov →What this trial is about
CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy (CHASE Study)
Who can take part
Age range
18 Years to 85 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Sign informed consent;
- Between the ages of 18 and 85;
- Clinical diagnosis of pulmonary hypertension, using or planning to use pulmonary hypertension targeted drugs (including any one or more of the following: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists and prostacyclin receptor agonists).
Exclusion criteria
- Have a history of mental illness or drug or poison addiction, and can not sign informed consent or can not cooperate with the experimental study;
- Patients with malignant tumor and other diseases and life expectancy of less than half a year;
- Short-term (less than 2 weeks) patients taking targeted drugs for pulmonary hypertension
Where it is running
1 location listed.
- Center for Respiratory and Pulmonary Vascular Diseases, Fuwai hospital, CAMS & PUMC - Beijing, China